DUBLIN—Allergan (NYSE: AGN) and its subsidiaries announced Thursday that the company has reached an agreement with InnoPharma Inc. resolving patent litigation regarding U.S. patents covering its Restasis dry eye drug, which are Orange book-listed and will expire on August 27, 2024. As a result of the settlement, all InnoPharma Hatch-Waxman litigation regarding Restasis patents will be dismissed.

Under the terms of the settlement, Allergan will grant InnoPharma licenses to market a generic version of Restasis in the U.S. beginning on February 24, 2024, or earlier under certain circumstances. Additionally, under certain circumstances, Allergan will supply and authorize InnoPharma to launch an authorized generic version of Restasis on August 28, 2024. Additional details regarding the settlement were not disclosed.